drugset / Trial / NCT00198172
Phase II Study of Cisplatin Plus Epirubicin Salvage Chemo in Refractory Germ Cell Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study proposes to evaluate the combination of cisplatin plus epirubicin in patients with refractory germ cell tumor not amendable to cure with surgery or standard platinum salvage chemotherapy. This regimen will be used in eligible patients after progression on ECOG Study E39897.
Timeline
- Start
- 2000-10
- Primary completion
- —
- Completion
- 2007-03
Outcome
Outcome not reported
Stopped (Enrollment): “Accrual Goal Met”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Epirubicin | Small molecule | — | — |